SKIP TO MAIN CONTENT

Keep patients moving toward recovery with once-monthly Sublocade®

Keep patients moving toward recovery with once-monthly Sublocade®

Relapse—it's not a failure, it's an opportunity to reassess treatment4,5

Addressing the drivers of opioid use disorder (OUD) could help disrupt the cycle of addiction.4

It takes more to block the rewarding effects of opioids than you may think6,7

At least 2 ng/mL (≥70% μORO) of buprenorphine was needed to block the rewarding effects of opioids.8

Your patients may benefit from consistent delivery of buprenorphine3

SUBLOCADE is designed to deliver continuous buprenorphine plasma levels to block the rewarding effects of opioids over the long term.3

Treatment considerations for opioid use disorder

Understanding the significance of 70% μORO

QUESTION 1 OF 4:
Consider an average patient being treated with buprenorphine for OUD who is offered an illicit substance. What may help reduce their vulnerability to illicit opioid use? Select all that apply

Please select an option.

Brain scan showing 70% μ-opioid receptor occupancy.

Both answers are correct—both counseling and managing μORO play important roles4,6,9

The exposure response relationship showed maximal decrease in illicit opioid use when buprenorphine plasma levels reached 2-3 ng/ml, which has been correlated to ≥70% μORO.1

Independent studies have shown that targeting μORO is an effective strategy for disrupting the drivers of OUD.4,7,9,10 At least 70% μORO by buprenorphine was needed to block the rewarding effects of opioids.8

From an analysis of whole-brain μORO in a representative patient, where parametric images of μORO at 4-, 28- and 76-hours following maintenance administration of 16 mg of transmucosal buprenorphine were analyzed.9

QUESTION 2 OF 4:
An average patient misses a dose of their prescribed buprenorphine for the treatment of OUD. What might the patient experience if receptor occupancy falls below the 70% target (which requires buprenorphine concentrations of greater than or equal to 2ng/ml)? Select all that apply.

Please select an option.

Brain scan showing 46% μ-opioid receptor occupancy.

At 28 hours, μORO is predicted to be less than 50%, potentially leaving the patient vulnerable to rewarding effects that could restart the cycle of OUD. Greater μORO is generally needed to control cravings.7-10

From an analysis of whole-brain μORO in a representative patient, where parametric images of μORO at 4-, 28- and 76-hours following maintenance administration of 16 mg of transmucosal buprenorphine were analyzed.9

QUESTION 3 OF 4:
For a patient who is struggling with addiction, what factors should be considered when helping them disrupt the negative consequences of OUD?
Select all that apply

Please select an option.



Brain scan showing 46% μ-opioid receptor occupancy. Brain scan showing 18% μ-opioid receptor occupancy.

Both answers are correct. If a patient is struggling to stick to a treatment plan after 28 hours without buprenorphine, their μORO could be around 46%, and after 76 hours, their μORO could be around 18%. When μORO drops below 70%, patients are more vulnerable to the rewarding effects of opioid use.2,8,9 In addition, data suggests that higher μORO is also needed to help reduce opioid craving.8,10

Independent studies showed that buprenorphine plasma levels and μORO are highly correlated.7,9,10 Buprenorphine plasma levels of at least 2 ng/mL were needed to achieve ≥70% μORO.8

From an analysis of whole-brain μORO in a representative patient, where parametric images of μORO at 4-, 28- and 76-hours following maintenance administration of 16 mg of transmucosal buprenorphine were analyzed.9

QUESTION 4 OF 4:
Which patient(s) being treated for OUD do you think may be more vulnerable to the rewarding effects of opioids? Select all that apply

Please select an option.

From an analysis of whole-brain μORO in a representative patient, where parametric images of μORO at 4-, 28- and 76-hours following maintenance administration of 16 mg of transmucosal buprenorphine were analyzed.9

PATIENT 1
(70% μORO)

PATIENT 2
(46% μORO)

PATIENT 3
(18% μORO)

Patients 2 and 3 may be more vulnerable to the rewarding effects of opioids. Patients can be more vulnerable to the rewarding effects of opioids when burprenorphine μORO is less than 70%. Consistent buprenorphine plasma levels of at least 2 ng/mL are required to achieve ≥70% μORO in order to block those effects.7-9

INDICATION

SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII) is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.

SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION
AND MITIGATION STRATEGY

  • Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
  • Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.

Prescription use of this product is limited under the Drug Addiction Treatment Act.

CONTRAINDICATIONS: SUBLOCADE should not be administered to patients who are hypersensitive to buprenorphine or any component of the ATRIGEL® delivery system.

WARNINGS AND PRECAUTIONS

Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Buprenorphine is sought by people with opioid use disorder and is subject to criminal diversion. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.

Risk of Life-Threatening Respiratory Depression and Concomitant Use of Benzodiazepines or Other CNS Depressants with Buprenorphine: Buprenorphine has been associated with life-threatening respiratory depression, overdose, and death, particularly when misused by self-injection or with concomitant use of benzodiazepines or other CNS depressants, including alcohol. Warn patients of the potential danger of self-administration of benzodiazepines, other CNS depressants, opioid analgesics, and alcohol while under treatment with SUBLOCADE. Counsel patients that such medications should not be used concomitantly unless supervised by a healthcare provider.

Use with caution in patients with compromised respiratory function (e.g., chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression).

Opioids can cause sleep-related breathing disorders; e.g., central sleep apnea (CSA), sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. Consider decreasing the opioid using best practices for opioid taper if CSA occurs.

Strongly consider prescribing naloxone at the time SUBLOCADE is initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose. Educate patients and caregivers on how to recognize respiratory depression and, if naloxone is prescribed, how to treat with naloxone. Emphasize the importance of calling 911 or getting emergency help, even if naloxone is administered.

Risk of Serious Injection Site Reactions: The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration, and necrosis. Some cases resulted in surgical depot removal, debridement, antibiotic administration, and SUBLOCADE discontinuation. The likelihood of serious injection site reactions may increase with inadvertent intramuscular or intradermal administration. Carefully review injection technique.

Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. NOWS may be life-threatening if not recognized and treated in the neonate. Newborns should be observed for signs of NOWS and managed accordingly. Advise pregnant women receiving opioid addiction treatment with SUBLOCADE of the risk of neonatal opioid withdrawal syndrome.

Adrenal Insufficiency: Adrenal insufficiency has been reported with opioid use. If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. Wean the patient off the opioid.

Discontinuation of SUBLOCADE Treatment: Due to the long-acting nature of SUBLOCADE, if treatment is discontinued, monitor patients for several months for withdrawal and treat appropriately.

Inform patients that they may have detectable levels of buprenorphine for a prolonged period of time after treatment with SUBLOCADE. Considerations of drug-drug interactions, buprenorphine effects, and analgesia may continue to be relevant for several months after the last injection.

Risk of Hepatitis, Hepatic Events: Because cases of cytolytic hepatitis and hepatitis with jaundice have been observed in individuals receiving buprenorphine, monitor liver function tests prior to treatment and monthly during treatment.

Hypersensitivity Reactions: Hypersensitivity to buprenorphine-containing products have been reported most commonly as rashes, hives, and pruritus. Some cases of bronchospasm, angioneurotic edema, and anaphylactic shock have also been reported.

Precipitation of Opioid Withdrawal in Patients Dependent on Full Agonist Opioids: Buprenorphine may precipitate opioid withdrawal signs and symptoms in persons who are currently physically dependent on full opioid agonists such as heroin, morphine, or methadone before the effects of the full opioid agonist have subsided. Verify that patients have tolerated and are dose adjusted on transmucosal buprenorphine before subcutaneously injecting SUBLOCADE.

Risks Associated With Treatment of Emergent Acute Pain: When patients need acute pain management, or may require anesthesia, treat patients receiving SUBLOCADE currently or within the last 6 months with a non-opioid analgesic whenever possible. If opioid therapy is required, patients may be treated with a high-affinity full opioid analgesic under the supervision of a physician, with particular attention to respiratory function, as higher doses may be required for analgesic effect and therefore, a higher potential for toxicity exists with opioid administration.

Advise patients of the importance of instructing their family members, in the event of emergency, to inform the treating healthcare provider or emergency room staff that the patient is physically dependent on an opioid and that the patient is being treated with SUBLOCADE.

Use in Opioid Naïve Patients: Because death has been reported for opioid naïve individuals who received buprenorphine sublingual tablet, SUBLOCADE is not appropriate for use in opioid naïve patients.

Use in Patients With Impaired Hepatic Function: Because buprenorphine levels cannot be rapidly decreased, SUBLOCADE is not recommended for patients with pre-existing moderate to severe hepatic impairment. Patients who develop moderate to severe hepatic impairment while being treated with SUBLOCADE should be monitored for several months for signs and symptoms of toxicity or overdose caused by increased levels of buprenorphine.

Use in Patients at Risk for Arrhythmia: Buprenorphine has been observed to prolong the QTc interval in some patients participating in clinical trials. Avoid use of buprenorphine in patients with a history of Long QT Syndrome or an immediate family member with this condition or those taking Class IA antiarrhythmic medications (e.g., quinidine, procainamide, disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, dofetilide), or other medications that prolong the QT interval.

Impairment of Ability to Drive or Operate Machinery: SUBLOCADE may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Caution patients about driving or operating hazardous machinery until they are reasonably certain that SUBLOCADE does not adversely affect their ability to engage in such activities.

Orthostatic Hypotension: Buprenorphine may produce orthostatic hypotension.

Elevation of Cerebrospinal Fluid Pressure: Buprenorphine may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation.

Elevation of Intracholedochal Pressure: Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract.

Effects in Acute Abdominal Conditions: Buprenorphine may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Unintentional Pediatric Exposure: Buprenorphine can cause severe, possibly fatal, respiratory depression in children who are accidentally exposed to it.

ADVERSE REACTIONS: Adverse reactions commonly associated with SUBLOCADE (≥5% of subjects) during clinical trials were constipation, headache, nausea, vomiting, increased hepatic enzymes, fatigue, and injection site pain and pruritus. This is not a complete list of potential adverse events. Please see the full Prescribing Information for a complete list.

DRUG INTERACTIONS

CYP3A4 Inhibitors and Inducers: Monitor patients starting or ending CYP3A4 inhibitors or inducers for potential over- or under-dosing.

Serotonergic Drugs: If concomitant use with serotonergic drugs is warranted, monitor for serotonin syndrome, particularly during treatment initiation, and during dose adjustment of the serotonergic drug.

Consult the full Prescribing Information for SUBLOCADE for more information on potentially significant drug interactions.

USE IN SPECIFIC POPULATIONS

Pregnancy: Opioid-dependent women on buprenorphine maintenance therapy may require additional analgesia during labor.

Lactation: Buprenorphine passes into the mother's milk. Advise breastfeeding women to monitor the infant for increased drowsiness and breathing difficulties.

Fertility: Chronic use of opioids may cause reduced fertility. It is not known whether these effects on fertility are reversible.

Geriatric Patients: Monitor geriatric patients receiving SUBLOCADE for sedation or respiratory depression.

To report pregnancy or side effects associated with taking SUBLOCADE, please call 1-877-782-6966.

See the full Prescribing Information including BOXED WARNING, and Medication Guide. For REMS information visit www.sublocadeREMS.com.

References:

  1. 1. SUBLOCADE [prescribing information]. North Chesterfield, VA: Indivior Inc.; 2021.
  2. 2. Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1);(suppl):1-7.
  3. 3. Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Population pharmacokinetics of a monthly buprenorphine depot injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials. Clin Pharmacokinet. 2020;60(4):527-540.
  4. 4. US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. US Department of Health and Human Services; 2016.
  5. 5. National Institute on Drug Abuse; 2007. Drugs, Brains, and Behavior: The Science of Addiction. NIH publication 18-DA-5605. https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction. Published April 2007. Revised July 2018. Accessed February 28, 2020.
  6. 6. Nasser AF, Greenwald MK, Vince B, et al. Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol. 2016;36(1):18-26.
  7. 7. Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. 2014;144:1-11.
  8. 8. Nasser AF, Heidbreder C, Gomeni R, et al. A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. Clin Pharmacokinet. 2014;53:813-824.
  9. 9. Greenwald MK, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry. 2007;61(1):101-110.
  10. 10. Greenwald MK, Johanson CE, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000-2009.